Nanobiotix Raises $100M in Global Offering, Extending Cash Runway to 2029
Event summary
- Nanobiotix closed a $100M global offering on May 26, 2026, including full exercise of underwriters' option for additional ADSs.
- Total issuance included 2.2M ordinary shares and 345K pre-funded warrants at €33.60 per share, a 14.92% discount to recent trading average.
- Proceeds allocation: <10% for JNJ-1900 (NBTXR3) development, 50-60% for Nanoprimer and other platforms, 30-40% for general corporate purposes.
- Funding extends working capital runway into 2029 based on current burn rate.
The big picture
This $100M raise positions Nanobiotix to advance its physics-based therapeutic platforms while maintaining financial flexibility. The substantial allocation to general corporate purposes suggests potential for strategic pivots or acquisitions. The offering comes amid growing competition in oncology innovation, where Nanobiotix's approach differentiates it from traditional biotech players.
What we're watching
- Execution Risk
- Whether Nanobiotix can deliver on its ambitious development plans given the flexible allocation of proceeds.
- Platform Diversification
- The pace at which Nanoprimer and other platforms advance compared to the company's flagship oncology programs.
- Cash Management
- How the company's actual burn rate compares to projections as it approaches the 2029 runway target.
Related topics